PT-141

Mechanism of Action

PT-141 (bremelanotide) is a cyclic peptide that acts as a melanocortin receptor agonist, specifically targeting melanocortin-4 (MC4) receptors in the central nervous system to influence sexual desire and arousal.

The compound works by activating melanocortin receptors located in key brain regions involved in sexual function, particularly the hypothalamus. When PT-141 binds to and activates MC4 receptors, it triggers downstream signaling cascades that ultimately modulate neurotransmitter pathways associated with sexual motivation and arousal. This central nervous system mechanism distinguishes PT-141 from peripherally-acting sexual dysfunction treatments.

The evidence base includes multiple completed Phase 2 and Phase 3 clinical trials evaluating PT-141's efficacy in premenopausal women with hypoactive sexual desire disorder and female sexual arousal disorder. These studies demonstrate the compound's therapeutic activity through melanocortin receptor modulation, though the precise molecular details of the downstream signaling pathways require further elucidation.

As a therapeutic peptide containing D-amino acids, PT-141 has enhanced stability compared to natural peptides, allowing for subcutaneous administration. The compound represents an example of how peptide-based therapies can selectively target specific receptor systems to address endocrine and sexual health conditions.

Clinical Note: The available evidence focuses primarily on female sexual dysfunction. While research suggests potential applications in male sexual disorders, the clinical evidence for this indication remains limited.

This information is for educational purposes only and should not replace consultation with a healthcare provider for personalized medical advice.

PT-141 (bremelanotide) is primarily investigated and used for the treatment of hypoactive sexual desire disorder (HSDD) in women. The compound has undergone clinical development through Phase 2 and Phase 3 trials, with completed studies focusing specifically on premenopausal women with sexual dysfunction.

Primary Clinical Application

Hypoactive Sexual Desire Disorder in Women: PT-141 has been evaluated in multiple clinical trials for treating HSDD in premenopausal women. Three completed clinical trials (NCT02338960, NCT02333071, and NCT01382719) have assessed its efficacy and safety profile for this indication. Two Phase 3 studies specifically evaluated PT-141's effectiveness in premenopausal women with HSDD, while an earlier Phase 2 trial examined its use in women with both female sexual arousal disorder and HSDD.

Emerging Applications Under Investigation

Recent systematic reviews suggest PT-141 is being examined as part of the broader landscape of emerging pharmacological therapies for female sexual dysfunction. The compound is also being considered within the context of therapeutic peptides that may have applications in:

• Aesthetic, metabolic, and endocrine conditions as part of the therapeutic peptide class
• Gerontology applications for healthy aging, though specific evidence for PT-141 in this context is limited
• Sexual health concerns in cancer survivors, particularly after breast and gynecologic cancer, though direct evidence for PT-141 in this population is not established

Potential Male Applications

There is emerging interest in whether bremelanotide should be considered for treating sexual arousal and desire disorders in men, though the clinical evidence base for this application appears to be in early development compared to the female HSDD indication.

Evidence Limitations

While PT-141 has completed Phase 3 trials for female HSDD, the available evidence primarily focuses on premenopausal women. The broader applications in metabolic conditions, aging, and male sexual dysfunction require further clinical investigation to establish efficacy and safety profiles in these populations.

This information is for educational purposes only and should not replace consultation with a healthcare provider for personalized medical advice.

Safety Profile of PT-141 (Bremelanotide)

Evidence Limitation: The provided evidence contains limited detailed safety information for PT-141/bremelanotide. The available data primarily consists of study titles and clinical trial registrations without full safety reports or detailed adverse event profiles.

Known Side Effects

Based on the available clinical trial evidence from completed Phase 2 and Phase 3 studies in premenopausal women, PT-141 has been evaluated for safety, though specific side effect profiles are not detailed in the provided evidence. The compound has progressed through multiple phases of clinical testing, suggesting an acceptable safety profile for regulatory advancement, but comprehensive adverse event data is not available in the current evidence set.

Contraindications and Precautions

The provided evidence does not contain specific contraindication information for PT-141. The clinical trials focused on premenopausal women with hypoactive sexual desire disorder and female sexual arousal disorder, but contraindications for other populations are not detailed.

Drug Interactions

No drug interaction data for PT-141 is available in the provided evidence.

Populations That Should Avoid PT-141

The clinical evidence provided is limited to studies in premenopausal women. Safety data for other populations, including:

• Postmenopausal women
• Men (though one review article mentions consideration for male sexual disorders)
• Pediatric populations
• Patients with cardiovascular conditions
• Patients with other medical comorbidities

is not available in the current evidence set.

Clinical Context

The available evidence shows PT-141 has been studied in multiple completed clinical trials, including Phase 2 and Phase 3 studies, suggesting regulatory bodies have found the safety profile acceptable for continued investigation. However, the specific safety parameters, monitoring requirements, and risk-benefit considerations are not detailed in the provided materials.

Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Patients should consult healthcare providers for personalized medical guidance regarding PT-141 use, contraindications, and safety monitoring.

Evidence Note: The safety profile presented here is limited by the available evidence, which lacks detailed adverse event reporting and comprehensive safety data from the referenced clinical trials.

Research Papers and Clinical Trials

The research on PT-141 (bremelanotide) spans several key areas, though detailed study results are not available from the evidence provided.

Clinical Trial Evidence:
Three major clinical trials have been completed examining bremelanotide's effectiveness for female sexual dysfunction. Two Phase 3 trials (NCT02338960 and NCT02333071) specifically evaluated the drug's efficacy and safety in premenopausal women with hypoactive sexual desire disorder (HSDD). An earlier Phase 2 trial (NCT01382719) studied bremelanotide in premenopausal women with both female sexual arousal disorder and HSDD. While these trials are marked as completed, specific sample sizes, methodologies, and results are not detailed in the available evidence.

Academic Research:
Recent publications suggest ongoing interest in bremelanotide's therapeutic applications. A 2026 systematic review examined clinical trial evidence for emerging pharmacological therapies for HSDD in women, which likely included bremelanotide among the treatments analyzed. Another 2026 publication questioned whether bremelanotide should be considered for treating sexual arousal and desire disorders in men, indicating research interest beyond its current approved indication for women.

Additional research has explored bremelanotide within broader contexts, including therapeutic peptides for aesthetic, metabolic, and endocrine conditions, and strategies for treating sexual health concerns after breast and gynecologic cancer treatment.

Evidence Limitations:
The available evidence provides titles and basic trial information but lacks specific details about study methodologies, participant numbers, primary endpoints, or clinical outcomes. More comprehensive data would be needed to fully assess the research foundation for PT-141's therapeutic applications.

This information is for educational purposes only and should not replace consultation with a healthcare provider.

Protocols

Based on available clinical trial evidence, PT-141 (bremelanotide) has been studied primarily in women with hypoactive sexual desire disorder (HSDD). However, the provided evidence does not contain specific dosing protocols or administration details from the completed Phase 2 and Phase 3 trials.

The clinical trials listed (NCT02338960, NCT02333071, and NCT01382719) investigated bremelanotide in premenopausal women with HSDD and female sexual arousal disorder, but the actual dosing regimens, administration routes, and frequency of use are not detailed in the available evidence.

While the literature mentions bremelanotide as an FDA-approved treatment and discusses its potential applications in sexual health, the specific protocols for clinical use are not provided in the referenced studies. The systematic review of pharmacological therapies for HSDD (PMID: 42254382) may contain relevant protocol information, but specific details are not available in the current evidence.

Important Disclaimer: This information is for educational purposes only and does not constitute personalized medical advice. PT-141/bremelanotide should only be used under the supervision of a qualified healthcare provider. Dosing, administration, and treatment protocols must be determined by a healthcare professional based on individual patient factors, medical history, and current FDA-approved prescribing information. Patients should consult with their healthcare provider for specific treatment recommendations and protocols.

The limited evidence available does not provide sufficient detail to describe comprehensive dosing and administration protocols for PT-141.

Outcomes

The evidence for PT-141 (bremelanotide) outcomes is primarily limited to studies in premenopausal women with hypoactive sexual desire disorder (HSDD), with the available literature providing only titles and basic trial information rather than detailed results data.

Clinical Trial Evidence:
Three completed clinical trials have evaluated PT-141/bremelanotide in premenopausal women:

• Two Phase 3 studies (NCT02338960 and NCT02333071) examining efficacy and safety in women with HSDD
• One Phase 2 study (NCT01382719) evaluating the compound in women with female sexual arousal disorder and/or HSDD

However, the specific measurable outcomes from these trials are not detailed in the available evidence.

Published Literature Findings:
The recent literature includes several relevant publications, but the available evidence consists only of titles without access to the actual study results or outcome data. Key areas of investigation appear to include:

• Clinical trial evidence on pharmacological therapies for HSDD in women
• Potential applications in men with sexual arousal and desire disorders
• Safety profiles and clinical applications of therapeutic peptides
• Use in post-cancer sexual health concerns

Evidence Limitations:
The strength of evidence for specific PT-141 outcomes is severely limited in this dataset. While multiple Phase 2 and Phase 3 trials have been completed, the actual results, biomarker changes, symptom improvements, and quantitative efficacy measures are not provided in the available abstracts or trial listings. Without access to the full study data, it is not possible to report specific measurable outcomes or assess the clinical significance of any observed effects.

This summary is based solely on available evidence and does not constitute medical advice. Patients should consult healthcare providers for personalized treatment recommendations.